MarketPulse

weight-loss drug

8 articles
BenzingaBenzinga··Vandana Singh

Novo Nordisk Wins FDA Nod for High-Dose Wegovy, Expanding GLP-1 Arsenal

Novo Nordisk wins FDA approval for Wegovy HD, a higher-dose version launching in April across 70,000+ U.S. pharmacies, despite modest stock decline.
NVOHIMSFDA approvalclinical trial
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly's Oral GLP-1 Drug Could Reshape Weight Loss Market as Novo Nordisk Faces Competition

Eli Lilly's orforglipron oral GLP-1 drug offers no food restrictions and dual obesity-diabetes approval potential, threatening Novo Nordisk's oral Wegovy dominance.
LLYNVOpharmaceutical competitionweight-loss drug
BenzingaBenzinga··Vandana Singh

Hims & Hers Settles Novo Nordisk Patent Dispute, Inks GLP-1 Partnership

Hims & Hers and Novo Nordisk end legal battle, partnering to distribute weight-loss drugs via telehealth. Stock surges 48.67% despite mixed guidance.
NVOHIMSguidance missearnings beat
BenzingaBenzinga··Vandana Singh

Pfizer's Weight-Loss Drug Wins China Approval, Intensifying GLP-1 Competition

Pfizer wins NMPA approval for weight-loss drug ecnoglutide in China, achieving 15.4% average weight loss in trials, intensifying competition as Novo Nordisk's Wegovy faces patent expiry.
PFELLYNVOclinical trialweight-loss drug
BenzingaBenzinga··Vandana Singh

Novo Nordisk's CagriSema Falls Short in Weight-Loss Trial Against Lilly's Tirzepatide

Novo Nordisk's CagriSema underperformed Eli Lilly's tirzepatide in weight-loss trials, delivering 20.2% versus 23.6% weight reduction, triggering stock declines amid intensifying obesity drug competition.
LLYNVOclinical trialtirzepatide
BenzingaBenzinga··Erica Kollmann

Novo Nordisk Stock Drops 16% After CagriSema Misses Efficacy Target

Novo Nordisk's stock fell 16% after CagriSema obesity drug failed to match Eli Lilly's tirzepatide in trial, showing weaker weight loss results and jeopardizing approval timeline.
LLYNVOclinical trialobesity market
BenzingaBenzinga··Vandana Singh

Novo Nordisk Shares Decline on CagriSema Trial Setback Versus Lilly Rival

Novo Nordisk shares plunged 13% after CagriSema obesity drug trial missed non-inferiority target versus Eli Lilly's tirzepatide, threatening competitive positioning.
LLYNVOFDA approvalclinical trial
BenzingaBenzinga··Namrata Sen

Eli Lilly Stockpiles $1.5B in Experimental Weight-Loss Drug Ahead of FDA Review

Eli Lilly stockpiles $1.5B of experimental weight-loss drug orforglipron ahead of expected April FDA approval decision, signaling management confidence.
LLYNVOFDA approvalpharmaceutical competition